Nuclear Regulatory Commission Sample Clauses

Nuclear Regulatory Commission. The Company shall have not received from the NRC any communication that would reasonably be expected to have a material adverse impact on the ability of the Company to secure a Combined Construction and Operating License for the subject reactor from the NRC.
Sample 1
AutoNDA by SimpleDocs
Nuclear Regulatory Commission. Xx. Xxxx X. Flynn, Director Division of Administrative Services Office of Administration Signature: Name: Xxxx X. Xxxxx Title: Director FOR THE VENDOR American Laser, Incorporated 0000 Xxxxxxx Xxxxxx Hyattsville, MD 20781 Email address: xxxxxxxx@xxx.xxx Signature: Name: Xxx Xxxxx
Sample 1
Nuclear Regulatory Commission. Under the Act, the NRC has the responsibility to provide informal review and consultation, monitor activities, and prescribe decommissioning criteria for the West 1 The NYSDOL was invited to participate in the Agreement, but it declined the offer (see letter from Xxxxxxx X. Xxxxx of the NYSDOL to Xxxx Xxxxxx of the NYSDEC, dated January 19, 2000). Valley Demonstration Project. Once the DOE fulfills its obligations under the Act, NYSERDA’s NRC license will be reactivated. The NRC will then be responsible for enforcement of the applicable NRC requirements regarding maintenance or closure and release of the WNYNSC, exclusive of the SDA. The NRC is responsible for regulating any off-site contamination (contamination of areas outside of the 3300 acres of the WNYNSC property) that results from NRC-licensed activity at the site. The NRC’s Director of the Office of Nuclear Material Safety and Safeguards is responsible for ensuring the implementation of the terms of this Agreement. The NRC’s West Valley Project Manager will be the NRC point of contact for all communications relating to carrying out the provisions of this Agreement. The Project Manager, on behalf of the NRC, will coordinate the exchange of written and oral information and comments between the NYSDEC and the NRC. New York State Department of Environmental Conservation As regulatory agencies representing New York State under the NRC Agreement State Program, the NYSDEC and the NYSDOL have now, and will retain, the radiological regulatory authority for the SDA and any areas outside of its boundary that are contaminated as a result of activities at the SDA. Additionally, the NYSDEC, pursuant to the authority delegated to it by the United States Environmental Protection Agency and the New York State Environmental Conservation Law, has regulatory responsibility for all issues related to the Resource Conservation and Recovery Act, Clean Air Act, Clean Water Act, and all other pertinent regulations, at the WNYNSC. The NYSDEC’s Director of the Bureau of Radiation and Hazardous Site Management is responsible for ensuring the implementation of the terms of this Agreement. The NYSDEC’s West Valley Project Manager will be the NYSDEC’s point of contact for all communications relating to carrying out the provisions of this Agreement. The Project Manager, on behalf of the NYSDEC, will coordinate the exchange of written and oral information and comments between the NYSDEC and the NRC.
Sample 1
Nuclear Regulatory Commission. PSCR.............................
Sample 1
Nuclear Regulatory Commission. The NRC has regulatory jurisdiction over all phases of the operation, construction (including plant modifications), licensing and decommissioning of Fermi 2. ENVIRONMENTAL MATTERS DETROIT EDISON Detroit Edison, in common with other electric utilities, is subject to applicable permit and associated record keeping requirements, and to increasingly stringent federal, state and local standards covering, among other things, particulate and gaseous stack emission limitations, the discharge of effluents (including heated cooling water) into lakes and streams and the handling and disposal of waste material.
Sample 1
Nuclear Regulatory Commission. The NRC: a) regulates the NSS in accordance with the roles and responsibilities established in the Atomic Energy Act of 1946, as amended and as prescribed in Title 10 of the CFR; b) will provide licensing oversight of the NSS, through decommissioning, until license termination; c) will consult with the other signatories and consulting parties, as requested; and d) will be offered the opportunity to review and comment on draft products associated with the PA and will provide those comments in a timely manner.
Sample 1

Related to Nuclear Regulatory Commission

  • Grievance Commissioner System This is to confirm the discussion of the parties during collective bargaining that they are committed to encouraging early discussion and resolution of labour relations issues at the local level and seek to resolve grievances in a timely and cost efficient manner. To that end, this is to confirm that pursuant to Article 8, the parties agree that the Employer and Union at individual nursing homes may agree to utilize the following process in order to resolve a particular grievance through the utilization of a joint mediation-arbitration procedure:

  • Information for Regulatory Compliance Each of the Company and the Depositary shall provide to the other, as promptly as practicable, information from its records or otherwise available to it that is reasonably requested by the other to permit the other to comply with applicable law or requirements of governmental or regulatory authorities.

  • FEDERAL MARITIME COMMISSION Ocean Transportation Intermediary License Applicants The Commission gives notice that the following applicants have filed an application for an Ocean Transportation Intermediary (OTI) license as a Non- Vessel-Operating Common Carrier (NVO) and/or Ocean Freight Forwarder (OFF) pursuant to section 19 of the telephone at (202) 523–5843 or by email at XXX@xxx.xxx. 5G Logistics Solutions LLC (NVO & OFF), 0000 XX 000xx Xxxxx, Xxxxx, XX 00000. Officers: Xxxxxxxx Xxxxxx, President (QI), Xxxxxxx X. Xxxxx, Vice President. Application Type: New NVO & OFF License. American Cargo International, Inc. (NVO & OFF), 0000 XX 00xx Xxxxxx, Miami, FL 33128. Officers: Xxxxx Xx Xxx, Vice President (QI), Xxxxx Xxxxxxxx, Member. Application Type: License Transfer to American Cargo International, LLC. Atlanta Customs Brokers & Intl Freight Forwarders Inc dba ACB Ocean Services (NVO & OFF), 000 Xxxxxxx Xxxxx Xxxxxxx, Xxxxx 000, Xxxxxxx, XX 00000. Officers: Xxxxx Xxxxxxxx, Vice President Exports (QI), Xxxxxx Xxxxxx, President. Application Type: New NVO & OFF License. Xxxxxxx International Transport, L.L.C. (NVO & OFF), 0000 Xxxxxxxxxx Xxxxxxx, XxXxxxxxx, XX 00000. Officers: Xxxxxx X. Xxxxxxxx, Vice President (QI), Xxxxxx X. Xxxxxx, Managing Member. Application Type: QI Change. CMS Shipping Agency, Inc. dba Atlantic Pacific Lines (NVO & OFF), 0000 Xxxxxxxx, Xxxxx 000, Xxxx Xxxx Xxxxxx, XX 00000. Officer: Xxxxxx Xxxxxxx, President (QI). Application Type: Name Change to Atlantic Pacific Lines, Inc, dba Atlantic Pacific Lines. DBN Carrier, Inc. (NVO), 000 X. Xxxxxxxx Avenue, Suite 5B, Los Angeles, CA 90036. Officers: Xxxxxxxxxx Xxxxxxxxxx, President (QI), Xxxxxxx Xxxxxxxxxx, Secretary. Application Type: New NVO License. Xxxxxx Xxxxxxxxx dba Galaxy Enterprises LA (NVO), 00000 Xxxxxxx Xxxx., Xxxxx 00, Xxxxxxx Xxxx, CA 91403. Officer: Xxxxxx Xxxxxxxxx, Sole Proprietor (QI). Application Type: New NVO License. Forward Systems Group, Inc. (NVO & OFF), 1915 NW 00xx Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxxxx Xxxxxxx, President (QI), Xxxxx X. Xxxxxxx, COO. Application Type: New NVO & OFF License. Xxxxx X. Xxxxx & Co. dba JJB Global Logistics Co., Ltd. dba JJB Inland Logistics JJB Link Logistics Company 0000 Xxxxxxxxxx Xxxx, Xxxxx 000, Xxxxxxx, XX 00000. Officers: Xxxxxx Xxxxxx, President (QI), Xxxxxx Xxxxx, Secretary. Application Type: New NVO & OFF License. NMC Logistics Solutions, Inc. (NVO & OFF), 0000 XX 00xx Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxxxx Xxxxxxx, President (QI), Xxxxx Xxxxxx, Secretary. Application Type: New NVO & OFF License. Platinum Cargo Logistics, Inc. (NVO & OFF), 00000 X. Xxx Xxxx Avenue, Torrance, CA 90501. Officers: Xxxxxx

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Securities Exchange Commission Certification The Corporation confirms that as at the date hereof it does not have a class of securities registered pursuant to Section 12 of the U.S. Exchange Act or a reporting obligation pursuant to Section 15(d) of the U.S.

  • Regulatory Cooperation In connection with any foreclosure, collection, sale or other enforcement of Liens granted to the Administrative Agent in the Collateral Documents, Parent will, and will cause its Restricted Subsidiaries to, reasonably cooperate in good faith with the Administrative Agent or its designee in obtaining all regulatory licenses, consents and other governmental approvals necessary or (in the reasonable opinion of the Administrative Agent or its designee) reasonably advisable to conduct all aviation operations with respect to the Collateral and will, at the reasonable request of the Administrative Agent and in good faith, continue to operate and manage the Collateral and maintain all applicable regulatory licenses with respect to the Collateral until such time as the Administrative Agent or its designee obtain such licenses, consents and approvals, and at such time Parent will, and will cause its Restricted Subsidiaries to, cooperate in good faith with the transition of the aviation operations with respect to the Collateral to any new aviation operator (including, without limitation, the Administrative Agent or its designee).

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.

  • Commission Approval The Parties understand and agree that this Agreement will be filed with the Commission for approval by such Commission (or the FCC if the Commission fails to act) pursuant to Section 252 of the Act. Each Party specifically reserves its right to judicial review of this Agreement under Section 252(e)(6) of the Act, or any other available remedy at law or equity. If the Commission, the FCC or any court rejects any portion of this Agreement, the Parties agree to meet and negotiate in good faith to arrive at a mutually acceptable modification of the rejected portion and any provisions that would be materially affected by deletion of the rejected portion; provided that such rejected portion shall not affect the validity of the remainder of this Agreement. The Parties acknowledge that nothing in this Agreement shall limit a Party's ability, independent of such Party's agreement to support and participate in the approval of this Agreement, to assert public policy issues relating to the Act, including challenging the validity of any portion of the Act or an FCC or Commission rule, order, Guideline or other determination made pursuant to the Act, or the application by CBT for suspension or modification of portions of the Act or rules pursuant to Section 251(f)(2) of the Act. In the event CBT obtains a suspension or modification of any portion of the Act or rules thereunder pursuant to Section 252(f)(2) of the Act, the Parties shall negotiate as necessary to incorporate the applicable terms and conditions of such suspension or modification and the Parties agree to negotiate as necessary in order to clarify the application of such suspension or modification to the terms of into this Agreement.

  • Regulatory Compliance a. Monitor compliance with the 1940 Act requirements, including:

Time is Money Join Law Insider Premium to draft better contracts faster.